Search Results - "Montenora, I"

Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records by Bernardeschi, P, Fiorentini, G, Dentico, P, Rossi, S, Turrisi, G, Del Conte, A, Giannessi, P G, Giustarini, G, Montenora, I

Get full text

Thalidomide plus Monthly High-dose Dexamethasone in Chemorefractory Myeloma. Results of a Phase II Clinical Study by Bernardeschi, P, Giustarini, G, Montenora, I, Turrisi, G, Dentico, P, Rossi, S, Turano, E, Fiorentini, G

“…Thalidomide is a potent anti-myeloma drug which can produce up to a 30-50% overall response rate (ORR) in pre-treated, chemorefractory multiple myeloma. Most…”
Get full text

Activity of cefiderocol against NDM-producing Enterobacterales from a regional outbreak in the Tuscany region, Italy by A. Bartolini, C. Niccolai, M. Coppi, E. Andreoli, L. Bianchi, T. Brunelli, C. Fornai, I. Montenora, M. Nardone, E. M. Parisio, E. Riccobono, S. Valentini, E. Mantengoli, A. Antonelli, T. Giani, G. M. Rossolini

Get full text

Chemoresistant Myeloma: Phase II Clinical Study with Low-Dose Thalidomide Plus High-Dose Dexamethasone by Bernardeschi, P., Dentico, P., Rossi, S., Fiorentini, G., Giustarini, G., Montenora, I., Turano, E.

“…Thalidomide produces a response rate from 32 to 66% of pre-treated myeloma patients with doses ranging from 100 to 800 mg/daily. Common, dose-related side…”
Get full text